Use of GAL3 antagonist for treatment of depression and/or anxiety and compounds useful in such methods

US7465750B2 · kind B2 · utility

Assignee

• H. LUNDBECK A/S · DK

Inventors

• Thomas Blackburn · Hoboken, US
• Michael Konkel · Fair Lawn, US
• Lakmal Boteju · Kendall Park, US
• Ian Jamie Talisman · Bethesda, US
• John Wetzel · Elmwood Park, US
• Mathivanan Packiarajan · Saddle Brook, US
• Heidi Chen · Wyckoff, US
• Hermo Jimenez · Hazelwood, US

Key dates

• Filing date: Sep 6, 2006
• Grant date: Dec 16, 2008
• Expiry date: Sep 6, 2026

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D417/12
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

This invention is directed to pyrimidine and indolone derivatives which are selective antagonists for the GAL3 receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a pharmaceutical composition made by combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject an amount of a compound of the invention effective to treat the subject's depression and/or anxiety. This invention also provides a method of treating depression and/or anxiety in a subject which comprises administering to the subject a composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a GAL3 receptor antagoni…